Jane Street’s Arcutis Biotherapeutics ARQT Stock Holding History

Jane Street’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.11M	Buy	131,800 +34,000	+35%	+$868K	﹤0.01%	4283
2025 Q4	$2.84M	Buy	97,800 +50,500	+107%	+$1.29M	﹤0.01%	4141
2025 Q3	$892K	Sell	47,300 -5,500	-10%	-$86.7K	﹤0.01%	6570
2025 Q2	$740K	Buy	52,800 +26,700	+102%	+$374K	﹤0.01%	6188
2025 Q1	$408K	Sell	26,100 -21,500	-45%	-$303K	﹤0.01%	7242
2024 Q4	$663K	Sell	47,600 -15,400	-24%	-$169K	﹤0.01%	6165
2024 Q3	$586K	Buy	+63,000	New	+$622K	﹤0.01%	6916
2023 Q3	–	Sell	-123,600	Closed	-$1.18M	–	8584
2023 Q2	$1.18M	Buy	+123,600	New	+$1.37M	﹤0.01%	4959
2022 Q3	–	Sell	-85,200	Closed	-$1.82M	–	9652
2022 Q2	$1.82M	Buy	+85,200	New	+$1.75M	﹤0.01%	4349

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street's ARQT Position: Q1 2026 in Review

Jane Street increased its Arcutis Biotherapeutics (ARQT) stake by 28% in Q1 2026, buying an estimated $1.59M and bringing the position to 283,623 shares worth $6.68M. The position accounts for ﹤0.01% of the portfolio, ranked #3089.

Jane Street first reported a position in ARQT in Q3 2020 and has held it in 16 quarters since. The position peaked at $6.8M in Q3 2025. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

Jane Street held 283,623 shares of Arcutis Biotherapeutics worth $6.68M as of Q1 2026.
Jane Street bought 62,197 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.59M.
Arcutis Biotherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #3089 holding.
Jane Street first reported a position in Arcutis Biotherapeutics in Q3 2020 and has held it in 16 quarters since.
Jane Street's Arcutis Biotherapeutics position peaked at $6.8M in Q3 2025.
269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.